The most common type of CTCL is mycosis fungoides (MF). Mycosis fungoides was so named by a French dermatologist in the 1800s due to the mushroom like tumors that developed on the skin of a ...
US FDA grants breakthrough therapy designation to Innate Pharma’s lacutamab for relapsed or refractory Sézary syndrome: Marseille, France Tuesday, February 18, 2025, 12:00 Hrs ...
GlobalData on MSN3d
Innate’s lacutamab gains FDA breakthrough therapy designationInnate Pharma has secured US Food and Drug Administration (FDA) breakthrough therapy designation for lacutamab to treat ...
Considering taking supplements to treat mycosis fungoides? Below is a list of common natural remedies used to treat or reduce the symptoms of mycosis fungoides. Follow the links to read common ...
Hosted on MSN11mon
Pipeline moves: Prospects drop after investigator-led trial of Roche’s Tecentriq terminatedThe Phase II trial (NCT03357224) evaluated Tecentriq in 26 patients with stage IIb-IV mycosis fungoides/Sezary syndrome and cutaneous T-cell lymphoma, who received previous systemic treatment.
Researchers sought to determine whether the CAR-T therapy volamcabtagene durzigedleucel (CTX130) would be effective in patients with T-cell lymphoma.
Denileukin diftitox (DAB IL-2) is a relatively novel agent for treating mycosis fungoides, and is FDA approved for this indication. DAB IL-2 is a fusion protein made through recombinant technology.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback